Advertisement

Early Intensification Therapy in High-Risk Childhood Acute Lymphocytic Leukemia: Lack of Benefit from High-Dose Methotrexate

  • G. E. Janka
  • K. Winkler
  • H. Juergens
  • U. Goebel
  • COALL Study Groups
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 30)

Abstract

The prognosis for acute lymphoblastic leukemia (ALL) in childhood has improved considerably in the last two decades. Intensive chemotherapy soon after diagnosis has made a major contribution to this success [3, 12, 14], especially in patients with adverse prognostic factors [6]. In COALL-80, a cooperative West German treatment study for ALL, high-risk patients received intensive combination chemotherapy after a modification of the West Berlin protocol BFM 79/81 [7]. In the subsequent study, COALL-82, high-dose methotrexate was added to the intensive phase regimen. The results of both studies, which included 95 high-risk patients, are reported in this paper.

Keywords

AAAA AAAA Intensive Phase Reinduction Therapy Methotrexate Infusion Acute Undifferentiated Leukemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. 1.
    Bleyer WA (1977) Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics. Cancer Treat Rep 61: 1419–1425PubMedGoogle Scholar
  2. 2.
    Borsa J, Whitmore GF (1969) Studies relating to the mode of action of methotrexate. III. In¬hibition of thymidylate synthetase in tissue culture cells and in cell-free systems. Mol Pharmacol 5: 318–332PubMedGoogle Scholar
  3. 3.
    Haas RJ, Janka G, Gaedicke G, Kohne E, Netzel B (1983) Therapy of acute lymphocytic leukemia in childhood with intermediate dose 13. methotrexate and CNS irradiation. Blut 47: 321–331PubMedCrossRefGoogle Scholar
  4. 4.
    Haghbin M, Murphy L, Tan CC, Clarkson BD, Thaler HT, Passe S, Burchenal J (1980) A long-term clinical follow-up of children with acute lymphoblastic leukemia treated with intensive chemotherapy regimens. Cancer 46: 241–252PubMedCrossRefGoogle Scholar
  5. 5.
    Heinle RW, Welch AD (1948) Experiments with pteroylglutamic acid and pteroylglu- 15. tamic acid deficiency in human leukemia (ab¬stract). J Clin Invest 27: 539PubMedGoogle Scholar
  6. 6.
    Henze G, Langermann HJ, Gadner H, Schel¬long G, Welte K, Riehm H (1981) Ergebnisse der Studie BFM 76/79 zur Behandlung der 16. akuten lymphoblastischen Leukämie bei Kin¬dern and Jugendlichen. Klin Padiatr 193: 28–40Google Scholar
  7. 7.
    Henze G, Langermann HJ, Fengler R, Brandeis M, Evers KG, Gadner H, Hinderfeld L, Jobke A, Kornhuber B, Lampert F, Lasson U, Ludwig R, Müller-Weihrich S, Neidhardt M, Nessler G, Niethammer D, Rister M, Ritter J, Schaaff A, Schellong G, Stollmann B, Treuner J, Wahlen W, Weinel P, Wehinger H, Riehm H (1982) Therapiestudie BFM 79/81 zur Behandlung der akuten lymphoblastischen Leukämie bei Kindern und Jugendlichen: Intensivierte Reinduktionstherapie für Patientengruppen mit unterschiedlichem Rezidivrisiko. Klin Padiatr 194: 195–203PubMedCrossRefGoogle Scholar
  8. 8.
    Jaffe N, Traggis D, Das L, Kim BS, Won H, Hann L, Moloney WC, Dohlwith A (1972) Comparison of daily and twice-weekly schedule of L-asparaginase in childhood leukemia. Pediatrics 49: 590–595PubMedGoogle Scholar
  9. 9.
    Janka-Schaub GE, Winkler K, Jürgens H, Goebel U, Gutjahr P, Spaar HJ (1986) Intermediate-dose methotrexate in the treatment of childhood acute lymphocytic leukaemia: lack of benefit during maintenance therapy following intensive induction therapy. Eur J Pediatr 145: 14–17PubMedCrossRefGoogle Scholar
  10. 10.
    Janka GE, Winkler K, Jürgens H, Göbel U, Gutjahr P, Spaar HJ (für die Mitglieder der COALL-Studien) (1986) Akute lymphoblastische Leukämie im Kindesalter: Die COALL-Studien. Klin Padiatr 198: 171–177PubMedCrossRefGoogle Scholar
  11. 11.
    Miller DR, Leikin S, Albo V, Sather H, Karon M, Hammond D (1981) Intensive therapy and prognostic factors in acute lymphoblastic, leukemia of childhood: CCG 141 (1981) Haematol Blood Transfus 26: 1–10Google Scholar
  12. 12.
    Riehm H, Gadner H, Welte K (1977) Die West-Berliner Studie zur Behandlung der akuten lymphoblastischen Leukämie des Kindes: Erfahrungsbericht nach 6 Jahren. Klin Padiatr 189: 89–102PubMedGoogle Scholar
  13. 13.
    Rivera G, Dahl GV, Bowman WP, Avery TL, Wood A, Aur RJ (1980) VM-26 and cytosine arabinoside combination chemotherapy for initial induction failures in childhood lymphocytic leukemia. Cancer 46: 1727–1730CrossRefGoogle Scholar
  14. 14.
    Sallan SE, Camitta BM, Cassady JR, Nathan DG, Frei E III (1978) Intermittent combination chemotherapy with adriamycin for childhood acute lymphoblastic leukemia: clinical results. Blood 51: 425–433PubMedGoogle Scholar
  15. 15.
    Sallan SE, Hitchcock-Bryan S, Gelber R, Cassady JR, Frei E III, Nathan DG (1983) Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res 43: 5601–5607PubMedGoogle Scholar
  16. 16.
    Warren RD, Nichols AP, Bender RA (1978) Membrane transport of methotrexate in human lymphoblastoid cell lines Cancer Res 38: 668–671PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • G. E. Janka
    • 1
  • K. Winkler
    • 1
  • H. Juergens
    • 2
  • U. Goebel
    • 2
  • COALL Study Groups
  1. 1.Department of Hematology and OncologyChildren’s Hospital University of HamburgGermany
  2. 2.Department of Hematology and OncologyChildren’s Hospital University of DüsseldorfFederal Republic of Germany

Personalised recommendations